drugset / Trial / NCT04507438

The Effect of Donepezil on Glycemic Control in Type II Diabetics

NCT04507438

Phase 2 Terminated 7 enrolled University of Maryland, Baltimore
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to establish the effectiveness of the drug Donepezil in treating Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the FDA to treat Type 2 Diabetes Mellitus and its use in this research is experimental. 50 patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) will be randomized to either the donepezil treatment group or the control group after screening. (25 patients in each arm; a total of 50 patients). Both men and women shall be enrolled.Donepezil shall be orally administered to the study group. Control group will get an orally administered placebo which is an inert compound, lactose. Wk0 will be the randomization visit. The patients will take the drug for 8 weeks and the last follow up visit will be the last day of week 8.

Timeline

Start
2019-07-12
Primary completion
2023-09-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Oral
Subject Donepezil Small molecule 10 mg Oral